AUPH vs AZN

AUPH exhibits mixed financial health with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, and no available Altman Z-Score limits distress risk assessment. The company shows robust profitability (ROE: 20.65%, Gross Margin: 80.16%) and strong recent earnings growth (YoY EPS +130%), yet trades above its Graham Number of $5.86 at a current price of $14.53, supported by a forward P/E of 15.54 that reflects growth optimism. Insider activity is bearish with recent selling, and technical trend is weak at 10/100, offsetting positive momentum from 1Y return of +81%. Analyst target of $16.67 suggests upside potential, but limited analyst coverage (6) and missing financial data constrain conviction.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.